Does the media prefer SANA or RNAC?

In the previous week, Sana Biotechnology had 3 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 5 mentions for Sana Biotechnology and 2 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 0.51 beat Sana Biotechnology's score of 0.26 indicating that Cartesian Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cartesian Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SLDB or RNAC?

In the previous week, Solid Biosciences had 2 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 4 mentions for Solid Biosciences and 2 mentions for Cartesian Therapeutics. Solid Biosciences' average media sentiment score of 0.58 beat Cartesian Therapeutics' score of 0.51 indicating that Solid Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cartesian Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer WVE or RNAC?

In the previous week, WAVE Life Sciences had 11 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 13 mentions for WAVE Life Sciences and 2 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 0.51 beat WAVE Life Sciences' score of -0.09 indicating that Cartesian Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment WAVE Life Sciences 0 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Cartesian Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RNAC or OLMA?

In the previous week, Olema Pharmaceuticals had 2 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 4 mentions for Olema Pharmaceuticals and 2 mentions for Cartesian Therapeutics. Olema Pharmaceuticals' average media sentiment score of 0.73 beat Cartesian Therapeutics' score of 0.51 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cartesian Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Olema Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RNAC or LXRX?

In the previous week, Cartesian Therapeutics and Cartesian Therapeutics both had 2 articles in the media. Cartesian Therapeutics' average media sentiment score of 0.51 beat Lexicon Pharmaceuticals' score of 0.00 indicating that Cartesian Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cartesian Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexicon Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cartesian Therapeutics (RNAC) Competitors

$7.87 -0.21 (-2.60%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$7.86 -0.01 (-0.19%)

As of 09/23/2026 07:30 PM Eastern

Compare

RNAC vs. SANA, SLDB, WVE, OLMA, and LXRX

Should you buy Cartesian Therapeutics stock or one of its competitors? Cartesian Therapeutics's main competitors and comparable companies include Sana Biotechnology (SANA), Solid Biosciences (SLDB), WAVE Life Sciences (WVE), Olema Pharmaceuticals (OLMA), and Lexicon Pharmaceuticals (LXRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cartesian Therapeutics compare to Sana Biotechnology?

Sana Biotechnology (NASDAQ:SANA) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

Sana Biotechnology has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-103.02%	-39.16%
Cartesian Therapeutics	-8,550.65%	N/A	-29.84%

Cartesian Therapeutics has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A
Cartesian Therapeutics	$2.80M	85.02	-$130.30M	-$5.94	N/A

Sana Biotechnology has a beta of 2.12, suggesting that its stock price is 112% more volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

In the previous week, Sana Biotechnology had 3 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 5 mentions for Sana Biotechnology and 2 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 0.51 beat Sana Biotechnology's score of 0.26 indicating that Cartesian Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cartesian Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

88.2% of Sana Biotechnology shares are owned by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are owned by institutional investors. 25.4% of Sana Biotechnology shares are owned by insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Sana Biotechnology currently has a consensus price target of $9.33, indicating a potential upside of 203.03%. Cartesian Therapeutics has a consensus price target of $32.60, indicating a potential upside of 314.23%. Given Cartesian Therapeutics' higher probable upside, analysts clearly believe Cartesian Therapeutics is more favorable than Sana Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Cartesian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Sana Biotechnology and Cartesian Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

In the previous week, Solid Biosciences had 2 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 4 mentions for Solid Biosciences and 2 mentions for Cartesian Therapeutics. Solid Biosciences' average media sentiment score of 0.58 beat Cartesian Therapeutics' score of 0.51 indicating that Solid Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cartesian Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cartesian Therapeutics has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A
Cartesian Therapeutics	$2.80M	85.02	-$130.30M	-$5.94	N/A

Solid Biosciences has a beta of 2.44, indicating that its share price is 144% more volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

Solid Biosciences currently has a consensus price target of $18.69, suggesting a potential upside of 133.07%. Cartesian Therapeutics has a consensus price target of $32.60, suggesting a potential upside of 314.23%. Given Cartesian Therapeutics' higher probable upside, analysts plainly believe Cartesian Therapeutics is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Cartesian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Solid Biosciences has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-71.35%	-60.58%
Cartesian Therapeutics	-8,550.65%	N/A	-29.84%

Summary

Cartesian Therapeutics beats Solid Biosciences on 8 of the 15 factors compared between the two stocks.

How does Cartesian Therapeutics compare to WAVE Life Sciences?

WAVE Life Sciences (NASDAQ:WVE) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

89.7% of WAVE Life Sciences shares are held by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are held by institutional investors. 24.3% of WAVE Life Sciences shares are held by company insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

WAVE Life Sciences has a beta of -1.3, meaning that its share price is 230% less volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market.

WAVE Life Sciences presently has a consensus target price of $22.31, suggesting a potential upside of 464.87%. Cartesian Therapeutics has a consensus target price of $32.60, suggesting a potential upside of 314.23%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, equities analysts clearly believe WAVE Life Sciences is more favorable than Cartesian Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76
Cartesian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

WAVE Life Sciences has a net margin of -309.73% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-309.73%	-50.36%	-40.06%
Cartesian Therapeutics	-8,550.65%	N/A	-29.84%

In the previous week, WAVE Life Sciences had 11 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 13 mentions for WAVE Life Sciences and 2 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 0.51 beat WAVE Life Sciences' score of -0.09 indicating that Cartesian Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	0 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Cartesian Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cartesian Therapeutics has lower revenue, but higher earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$42.73M	18.22	-$204.38M	-$1.09	N/A
Cartesian Therapeutics	$2.80M	85.02	-$130.30M	-$5.94	N/A

Summary

WAVE Life Sciences and Cartesian Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Olema Pharmaceuticals?

Cartesian Therapeutics (NASDAQ:RNAC) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

Olema Pharmaceuticals has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-8,550.65%	N/A	-29.84%
Olema Pharmaceuticals	N/A	-48.26%	-43.04%

87.0% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 37.2% of Cartesian Therapeutics shares are owned by company insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cartesian Therapeutics has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$2.80M	85.02	-$130.30M	-$5.94	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.12	N/A

Cartesian Therapeutics has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 1.98, meaning that its share price is 98% more volatile than the broader market.

Cartesian Therapeutics currently has a consensus target price of $32.60, suggesting a potential upside of 314.23%. Olema Pharmaceuticals has a consensus target price of $40.60, suggesting a potential upside of 359.80%. Given Olema Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Cartesian Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Olema Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

In the previous week, Olema Pharmaceuticals had 2 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 4 mentions for Olema Pharmaceuticals and 2 mentions for Cartesian Therapeutics. Olema Pharmaceuticals' average media sentiment score of 0.73 beat Cartesian Therapeutics' score of 0.51 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cartesian Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Olema Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Olema Pharmaceuticals beats Cartesian Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Lexicon Pharmaceuticals?

Cartesian Therapeutics (NASDAQ:RNAC) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Cartesian Therapeutics currently has a consensus target price of $32.60, indicating a potential upside of 314.23%. Lexicon Pharmaceuticals has a consensus target price of $4.55, indicating a potential upside of 120.87%. Given Cartesian Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Cartesian Therapeutics is more favorable than Lexicon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

87.0% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 37.2% of Cartesian Therapeutics shares are owned by company insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cartesian Therapeutics has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market.

In the previous week, Cartesian Therapeutics and Cartesian Therapeutics both had 2 articles in the media. Cartesian Therapeutics' average media sentiment score of 0.51 beat Lexicon Pharmaceuticals' score of 0.00 indicating that Cartesian Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cartesian Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexicon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lexicon Pharmaceuticals has a net margin of -147.38% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-8,550.65%	N/A	-29.84%
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%

Lexicon Pharmaceuticals has higher revenue and earnings than Cartesian Therapeutics. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$2.80M	85.02	-$130.30M	-$5.94	N/A
Lexicon Pharmaceuticals	$49.80M	18.41	-$50.34M	-$0.15	N/A

Summary

Cartesian Therapeutics beats Lexicon Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Get Cartesian Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNAC vs. The Competition

Export

Metric	Cartesian Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$244.46M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-1.32	13.88	274.08	25.69
Price / Sales	85.02	1,343.77	638.21	78.99
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	-1.62	15.40	10.47	6.32
Net Income	-$130.30M	-$22.82M	$3.49B	$359.73M
7 Day Performance	0.13%	-1.70%	-0.67%	0.17%
1 Month Performance	-21.77%	-6.17%	-3.17%	-3.27%
1 Year Performance	-21.85%	30.67%	15.14%	5.58%

Cartesian Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNAC Cartesian Therapeutics	2.1137 of 5 stars	$7.87 -2.6%	$32.60 +314.2%	-19.8%	$244.46M	$2.80M	N/A	75	News Coverage
SANA Sana Biotechnology	2.8843 of 5 stars	$3.16 -1.3%	$9.33 +195.4%	-5.5%	$957.95M	N/A	N/A	142
SLDB Solid Biosciences	2.3999 of 5 stars	$8.37 -4.2%	$18.75 +124.0%	+50.5%	$937.15M	N/A	N/A	121
WVE WAVE Life Sciences	2.6421 of 5 stars	$4.46 -2.6%	$22.31 +400.3%	-42.2%	$902.48M	$42.73M	N/A	317	Trending News Analyst Forecast
OLMA Olema Pharmaceuticals	2.8899 of 5 stars	$9.78 -5.0%	$40.60 +315.1%	+0.5%	$900.35M	N/A	N/A	150	Analyst Upgrade Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNAC) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cartesian Therapeutics (RNAC) Competitors

RNAC vs. SANA, SLDB, WVE, OLMA, and LXRX

How does Cartesian Therapeutics compare to Sana Biotechnology?

Summary

How does Cartesian Therapeutics compare to Solid Biosciences?

Summary

How does Cartesian Therapeutics compare to WAVE Life Sciences?

Summary

How does Cartesian Therapeutics compare to Olema Pharmaceuticals?

Summary

How does Cartesian Therapeutics compare to Lexicon Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAC vs. The Competition

Cartesian Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cartesian Therapeutics (RNAC) Competitors

RNAC vs. SANA, SLDB, WVE, OLMA, and LXRX

How does Cartesian Therapeutics compare to Sana Biotechnology?

Is SANA or RNAC more profitable?

Which has better earnings & valuation, SANA or RNAC?

Which has more volatility and risk, SANA or RNAC?

Does the media prefer SANA or RNAC?

Do institutionals and insiders believe in SANA or RNAC?

Do analysts prefer SANA or RNAC?

Summary

How does Cartesian Therapeutics compare to Solid Biosciences?

Does the media favor SLDB or RNAC?

Do institutionals and insiders have more ownership in SLDB or RNAC?

Which has preferable earnings and valuation, SLDB or RNAC?

Which has more volatility & risk, SLDB or RNAC?

Do analysts recommend SLDB or RNAC?

Is SLDB or RNAC more profitable?

Summary

How does Cartesian Therapeutics compare to WAVE Life Sciences?

Do institutionals and insiders hold more shares of WVE or RNAC?

Which has more volatility and risk, WVE or RNAC?

Do analysts prefer WVE or RNAC?

Is WVE or RNAC more profitable?

Does the media prefer WVE or RNAC?

Which has higher earnings & valuation, WVE or RNAC?

Summary

How does Cartesian Therapeutics compare to Olema Pharmaceuticals?

Is RNAC or OLMA more profitable?

Do insiders and institutionals have more ownership in RNAC or OLMA?

Which has higher earnings and valuation, RNAC or OLMA?

Which has more risk & volatility, RNAC or OLMA?

Do analysts rate RNAC or OLMA?

Does the media favor RNAC or OLMA?

Summary

How does Cartesian Therapeutics compare to Lexicon Pharmaceuticals?

Do analysts recommend RNAC or LXRX?

Do institutionals and insiders believe in RNAC or LXRX?

Which has more volatility & risk, RNAC or LXRX?

Does the media refer more to RNAC or LXRX?

Is RNAC or LXRX more profitable?

Which has higher earnings & valuation, RNAC or LXRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAC vs. The Competition

Cartesian Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools